Witryna01-Dec-2014. $739K. $739K. 00.000. Completed. Generating Revenue. To view Nanna Therapeutics’s complete valuation and funding history, request access ». WitrynaNanna Therapeutics 1.858 Follower:innen auf LinkedIn. Disease-modifying Medicines Nanna Therapeutics is a small-molecule focused therapeutics biotech subsidiary of …
Phico Therapeutics Ltd. LinkedIn
WitrynaNanna Therapeutics are ambitiously delivering a range of novel therapeutics by addressing severe disorders including mitochondrial function as well as other areas. … Witryna20 paź 2024 · Cambridge Enterprise: commercialising your research-based IP; Contacts for industry; Training/ Professional Development . For our researchers . Patient and … hydroxyzine peak onset duration
安斯泰来收购独特筛查平台 助力线粒体疾病药物研发_答魔科研
Witryna13 lis 2024 · As well as co-founding the disruptive therapeutics company, Sulantrix, in 2024, David co-founded the mitochondrial therapy company, Nanna Therapeutics (sold to Astellas Pharma in 2024), the antibiotics company, Discuva (sold to Summit plc in 2024) and the oncology drug discovery company Sareum (IPO’d in 2004). WitrynaNanna Therapeutics has built a unique, game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. ... 260 Cambridge Science Park Milton Rd, Cambridge, Cambridgeshire, CB4 0WE, United Kingdom. Phone Number +44 1223423506. Website. www.nannatherapeutics.com. Revenue <$5M. WitrynaNANNA THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, … hydroxyzine renal adjustment